Table 1.

Systematic reviews of adherence to adjuvant endocrine therapy

TamoxifenAromatase inhibitor
Adherence (range)a,b41%–88%52%–91%
Therapy discontinuation (range)a15%–20% within year 15%–25% within 2 years
Five-year therapy discontinuation from meta-regression analysisb47.2% (95% CI, 41.1%–53.5%)31.0% (95% CI, 25.9 %–37.5%)
  • aMurphy et al. (21).

  • bHuiart et al. (22).